Myriad announce publication of validation of FirstGene Multiple Prenatal Screen

Myriad Genetics (MYGN) announced the publication of the analytical validation of the FirstGene Multiple Prenatal Screen in Clinical Chemistry. The study showed that each component of the test had exceptional sensitivity and specificity. Titled “Simultaneous prenatal cfDNA screening of aneuploidy, recessive single-gene conditions, and fetomaternal blood compatibility,” the study used nearly 500 samples to assess the multiple components of the FirstGene screen, including fetal aneuploidy testing, RhD compatibility, and recessive condition status in the pregnant person and fetus, including 19 prevalent and severe conditions. It found that every component of the test had greater than or equal to98.2% analytical sensitivity and greater than or equal to99.0% analytical specificity.